| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3591 |
| Trial ID | NCT06045910 |
| Disease | Non-Hodgkin's Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Follicular Lymphoma | B-Cell Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | ALETA-001 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A Cancer Research Phase I/ II Trial of ALETA-001 in Participants Who Do Not Achieve or Maintain an Optimal Response to Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Malignancies |
| Year | 2024 |
| Country | United Kingdom |
| Company sponsor | Cancer Research UK |
| Other ID(s) | CRUKD/23/001|IRAS ID: 1007028 |
| Cohort 1 | |||||||
|
|||||||